Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Blau

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
British Journal of Haematology|December 22, 2017
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow TransplantationAlicia Rovó, Austin Kulasekararaj, Michael Medinger, et al.
Haematologica|June 11, 2011
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trialTapani Ruutu, Liisa Volin, Dietrich W Beelen, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Haematologica|October 12, 2019
Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
British Journal of Haematology|December 22, 2017
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow TransplantationAlicia Rovó, Austin Kulasekararaj, Michael Medinger, et al.
Haematologica|June 11, 2011
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trialTapani Ruutu, Liisa Volin, Dietrich W Beelen, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Haematologica|October 12, 2019
Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working PartyOlaf Penack, Christophe Peczynski, Steffie van der Werf, et al.
BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Pageof 13